Form 4: Akero CTO's Equity Converted in Novo Nordisk Merger

Akero Therapeutics Chief Technology Officer Scott A. Gangloff's equity holdings were converted into cash and contingent value rights following the merger with Novo Nordisk.

Summary

• Scott A. Gangloff, Chief Technology Officer of Akero Therapeutics, Inc., reported the disposition of his beneficial ownership in the company.
• The dispositions occurred on December 9, 2025, as a direct result of the merger between Akero Therapeutics, Inc. and NN Invest Sub, Inc., a wholly-owned subsidiary of Novo Nordisk A/S.
• At the effective time of the merger, each share of Akero Therapeutics common stock was cancelled and converted into the right to receive $54.00 in cash (Closing Consideration) and one contractual contingent value right (CVR) representing the right to receive an additional $6.00 in cash if a specified milestone is achieved.
• Company Restricted Stock Units (RSUs) held by the reporting person were deemed fully vested, cancelled, and converted into the same merger consideration (cash and CVRs).
• Company Stock Options, whether vested or not, were deemed fully vested, cancelled, and converted into a cash payment equal to the product of the excess of the Closing Consideration ($54.00) over the option's exercise price, multiplied by the number of shares subject to the option, plus one CVR for each such share.
• The reported dispositions include 5,088 shares of Common Stock, 21,263 Company RSUs, and a total of 296,100 Company Stock Options (17,784 options at $19.62, 73,700 options at $29.23, and 204,616 options at $19.62).

Sentiment

Score: 7

Explanation: The filing reports the successful completion of a merger, converting equity into a defined cash value and a contingent upside, which is generally a positive outcome for shareholders of the acquired company, albeit with the uncertainty of the CVR.

Positives

• The reporting person's equity holdings were converted into a defined cash payment and a contingent value right, providing liquidity and potential upside.
• The merger consideration of $54.00 cash plus a CVR for $6.00 (total potential $60.00) provides a clear valuation for the acquired equity.

Negatives

• Akero Therapeutics, Inc. ceased to be an independent publicly traded entity, becoming a wholly-owned subsidiary of Novo Nordisk A/S.

Risks

• The $6.00 contingent value right (CVR) is dependent on the achievement of a specified milestone, meaning the full potential merger consideration of $60.00 is not guaranteed.

Future Outlook

Akero Therapeutics, Inc. is now a wholly-owned subsidiary of Novo Nordisk A/S. The future financial performance and strategic direction will be determined by Novo Nordisk. The contingent value right offers a potential future payment of $6.00 per share upon achievement of a specified milestone.

Industry Context

This acquisition by Novo Nordisk A/S of Akero Therapeutics, Inc. is consistent with a broader trend in the pharmaceutical and biotechnology industry where larger, established companies acquire smaller firms to expand their pipeline, particularly in promising therapeutic areas. Such mergers often provide significant returns for the acquired company's shareholders and integrate innovative assets into the acquirer's portfolio.

Stakeholder Impact

• Shareholders of Akero Therapeutics: Received $54.00 cash per share and one CVR for $6.00, providing liquidity and potential future upside.
• Employees (including reporting person): Equity awards converted into cash and CVRs, providing a financial exit from their holdings.
• Novo Nordisk A/S: Successfully acquired Akero Therapeutics, integrating its assets and potentially its team.

Next Steps

• Achievement of the specified milestone for the $6.00 CVR payment.
• Integration of Akero Therapeutics into Novo Nordisk's operations.

Key Dates

Keywords

Akero Therapeutics, Novo Nordisk, Merger, Acquisition, Form 4, Beneficial Ownership, Contingent Value Right, CVR, Biotechnology, Pharmaceuticals